BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16337379)

  • 1. Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution.
    Yamazaki K; Kusunose N; Fujita K; Sato H; Asano S; Dan A; Kanaoka M
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1371-9. PubMed ID: 16337379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
    Dan A; Shiyama T; Yamazaki K; Kusunose N; Fujita K; Sato H; Matsui K; Kitano M
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4085-90. PubMed ID: 16005625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example.
    Castro A; Jerez MJ; Gil C; Calderón F; Doménech T; Nueda A; Martínez A
    Eur J Med Chem; 2008 Jul; 43(7):1349-59. PubMed ID: 18082290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
    Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
    J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
    Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
    Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for generating less toxic P-selectin inhibitors: pharmacophore modeling, virtual screening and counter pharmacophore screening to remove toxic hits.
    Ananthula RS; Ravikumar M; Pramod AB; Madala KK; Mahmood SK
    J Mol Graph Model; 2008 Nov; 27(4):546-57. PubMed ID: 18993099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
    Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
    Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A discussion of measures of enrichment in virtual screening: comparing the information content of descriptors with increasing levels of sophistication.
    Bender A; Glen RC
    J Chem Inf Model; 2005; 45(5):1369-75. PubMed ID: 16180913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
    Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the virtual screening paradigm: structure-based searching for new lead compounds.
    Schlosser J; Rarey M
    J Chem Inf Model; 2009 Apr; 49(4):800-9. PubMed ID: 19354328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
    Durgam GG; Virag T; Walker MD; Tsukahara R; Yasuda S; Liliom K; van Meeteren LA; Moolenaar WH; Wilke N; Siess W; Tigyi G; Miller DD
    J Med Chem; 2005 Jul; 48(15):4919-30. PubMed ID: 16033271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
    Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
    Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating virtual screening in lead discovery.
    Oprea TI; Matter H
    Curr Opin Chem Biol; 2004 Aug; 8(4):349-58. PubMed ID: 15288243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
    Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
    Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
    Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
    Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors.
    Rella M; Rushworth CA; Guy JL; Turner AJ; Langer T; Jackson RM
    J Chem Inf Model; 2006; 46(2):708-16. PubMed ID: 16563001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.